- Companies
- Surmodics
Surmodics Acquisition & Valuation
Surmodics was acquired by GTCR for $627M in May 2024, a 19.6x multiple on $32M of revenue.
Surmodics acquisition price
$627M
Acquired by GTCR · May 2024
Surmodics revenue at acquisition
$32M
Last twelve months · May 2024
Surmodics revenue multiple at acquisition
19.6x
EV/Revenue · May 2024
Surmodics Overview
About Surmodics
Surmodics is a provider of medical device coatings, including the largest U.S. supplier of hydrophilic coatings for catheters and guidewires, along with in vitro diagnostic technologies for the healthcare industry. Its device portfolio includes thrombectomy catheters such as the Pounce arterial thrombus retrieval system and the ReVene venous thrombectomy catheter, along with minimally invasive catheter technologies for complex interventional procedures. Surmodics serves medical device manufacturers and healthcare providers across catheter-based and vascular procedures.
HQ
Website
Status
Acquired
Customer focus
B2B
Revenue model
Product sales
Revenue
$32M (May 2024)
Valuation
$627M (acquired May 2024)
Surmodics Acquisition
Surmodics was acquired by GTCR for $627M on 29 May 2024.
The acquisition price implies a 19.6x revenue multiple on $32M of revenue.
Surmodics, Inc., a provider of medical device coatings, including the largest U.S. supplier of hydrophilic coatings for catheters and guidewires, and in vitro diagnostic technologies to the healthcare industry, entered into a definitive merger agreement on May 29, 2024, to be acquired by affiliates of GTCR, a private equity firm with extensive expertise in healthcare and healthcare technology. GTCR will acquire all outstanding shares for $43.00 per share in cash, valuing the equity at approximately $627 million, a 41.1% premium to Surmodics’ 30-trading day volume-weighted average closing price through May 28, 2024. The deal is financed through committed equity from GTCR funds and debt financing; upon closing, Surmodics will become privately held and delist from Nasdaq. Surmodics’ board unanimously approved the transaction and recommended shareholder approval, with CEO Gary Maharaj highlighting GTCR’s domain expertise as ideal for future growth in serving physicians, patients, and customers. Needham analysts noted the deal’s fair valuation and lack of major antitrust risks despite GTCR’s prior investment in Biocoat, another coatings developer, suggesting potential cost-saving synergies as their combined market shares remain low. The transaction faced FTC scrutiny over alleged 50-60% control in outsourced hydrophilic coatings, high HHI increases exceeding 1,000, and loss of head-to-head competition, prompting a July 29, 2025, divestiture to Integer of 10 Biocoat products, 11 employees, a production facility, and partial customer contracts. A U.S. District Court in Illinois denied the FTC’s November 2025 preliminary injunction motion on November 10, 2025, citing the divestiture’s effectiveness, business testimony, and a strong defense expert; regulators chose not to appeal. As of November 17, 2025, Surmodics expected prompt closing subject to customary conditions including no material adverse effects, shareholder approval, and absence of legal restraints, originally targeted for H2 2024 but delayed by regulatory review.
| Acquirer | Date | Type | Price | EV/Revenue |
|---|---|---|---|---|
| 29 May 2024 | PE buyout | $627M | 19.6x |
Acquisitions by Surmodics
Surmodics has acquired 3 companies to date.
Last acquisition by Surmodics was on July 6th 2021. Surmodics acquired Vetex Medical for $40M.
Latest Acquisitions by Surmodics
| Description | Vetex Medical is a Galway-based medical device firm developing thrombectomy catheters for venous thromboembolism treatment. The company's platform technology targets deep vein thrombosis in ilio-femoral veins, AV fistula grafts, and pulmonary embolism, enabling single-session thrombus removal. Incorporated in 2013, Vetex Medical has secured CE Mark approval for its device and initiated U.S. FDA pivotal trials in 2022. Its catheters feature helical basket designs for efficient clot retrieval, addressing a market projected to exceed $1 billion by 2025, with clinical data from over 50 procedures demonstrating 90% success rates. | - | Creagh Medical is a Cork-headquartered Irish manufacturer of angioplasty balloons for cardiovascular interventions. The firm designs and produces high-pressure compliant and non-compliant balloons used in percutaneous transluminal coronary angioplasty procedures. It supplies medical device companies worldwide with components meeting ISO 13485 standards. |
| HQ Country | |||
| HQ City | Galway | - | Ballinasloe |
| Deal Date | 6 Jul 2021 | 11 Jan 2016 | 20 Nov 2015 |
| Valuation | $40M | $14M | $32M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Surmodics acquisitions and their M&A valuation multiples. Start Free Trial | |||
Surmodics Competitors
Surmodics competitors include listed companies like Cerus, Shinva, Universal Vision and AngioDynamics, and private ones like Galvanize Therapeutics and Delfi Diagnostics.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $206M | ($5M) | $536M | 2.2x | ||
| Publicly listed | $1.5B | $126M | $1.1B | 0.6x | ||
| Publicly listed | $132M | $58M | $358M | 2.7x | ||
| Publicly listed | $320M | ($13M) | $635M | 1.8x | ||
| Private | - | - | $650M | - | ||
| Private | - | - | $685M | - |
Surmodics Public Comps
Surmodics is no longer listed, but its public comps include AngioDynamics, Oculis Holding, Nanosonics, Lumibird, SS Innovations, Curiox Biosystems, Salus, Sunmax Biotechnology, UltraGreen.ai and Cytek Biosciences.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $320M | ($13M) | 1.8x | 1.8x | (44.5x) | 34.3x | |||
| - | ($121M) | - | 283.0x | (2.8x) | (3.3x) | |||
| $145M | $18M | 3.6x | 3.5x | 29.6x | 31.1x | |||
| $263M | $48M | 2.8x | 2.7x | 15.5x | 12.7x | |||
| $42M | ($7M) | 15.5x | 12.0x | (92.4x) | (71.9x) | |||
| $4M | ($17M) | 156.6x | - | (33.9x) | - | |||
| $802M | $32M | 0.9x | - | 22.2x | - | |||
| $64M | $35M | 10.2x | - | 18.6x | - | |||
This data is available for Pro users. Sign up to see all Surmodics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Surmodics
| Where is Surmodics headquartered? | Surmodics is headquartered in United States. |
| Is Surmodics publicly listed? | No, Surmodics was acquired by GTCR in May 2024. |
| Who acquired Surmodics? | Surmodics was acquired by GTCR in May 2024. |
| How much was Surmodics acquired for? | Surmodics was acquired for $627M in May 2024, a 19.6x revenue multiple. |
| Which companies are comparable to Surmodics? | Companies comparable to Surmodics include Cerus, Shinva, Universal Vision, AngioDynamics, Galvanize Therapeutics and Delfi Diagnostics. |
| How many companies has Surmodics acquired? | Surmodics has acquired 3 companies, including Vetex Medical, NorMedix and Creagh Medical. |
| What was the largest acquisition by Surmodics? | The $40M acquisition of Vetex Medical in July 2021 is the largest acquisition Surmodics has made to date. |
See companies similar to Surmodics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




